Gilead Drug Shows COVID-19 Isn't Guaranteed  'Death Sentence,' Jim Cramer Says

Katherine Ross

Let's go over the markets. 

Stocks rose Wednesday as investors embraced positive news on a drug to combat the coronavirus and looked past data that showed a sharp contraction in U.S. growth in the first quarter.

Gilead's remdesivir received some positive news on Wednesday. 

Gilead said the drug met a government study primary endpoint.

Remdesivir is being tested in multiple clinical trials and it is being used to treat severely ill COVID-19 patients who have been hospitalized.

The study is being conducted by the National Institute of Allergy and Infectious Diseases. 

Meanwhile, growth in the U.S. registered its first contraction in six years and its sharpest drop since the last recession during the first quarter as the coronavirus pandemic shut down the economy.

Watch the full video above for Cramer's full take.

Want to know what Jim Cramer and his team at Action Alerts PLUS are thinking about the markets and the stocks they're watching? Sign up on Action Alerts PLUS for more.

Cramer and the team are weighing in on what members need to know about the coronavirus pandemic's impact on the market. Here's how you can recap his entire April show.

Watch More of the Latest Videos on TheStreet and Jim Cramer

Enter your email to register or login. Registration information may be shared with advertising partners in accordance with our Privacy Policy.